You Position: Home > Paper
The efficacy and safety of bortezomib treatment in 12 patients with refractory multiple myeloma
( views:277, downloads:29 )
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 5
- DOI:
- 10.3760/cma.j.issn.1009-9921.2007.05.005
- Key Word:
- 硼替佐米;多发性骨髓瘤;难治病;治疗
Abstract： 目的 观察硼替佐米治疗难治性多发性骨髓瘤(MM)的疗效和患者不良反应.方法 12例患者中男9例,女3例,中位年龄67岁,难治性MM患者接受硼替佐米治疗,1.0 mg/m2～1.3 mg/m2,静脉注射,第1、4、8、11天,3周为1个疗程;或者1.6mg/m2静脉注射,第1、8、15、22天,5周1个疗程.多数患者同时应用地塞米松20～40mg/d,第1天至第4天;2例同时合用多柔比星脂质体(商品名:楷莱).疗效采用EBMT标准进行评价,不良反应按照美国国立癌症研究所(NCI)CTCAE评价.结果 中位随访时间6.5(1～13)个月,9例可评价疗效,8例(88.9%)有效,其中nCR4例,PR3例,MR1例.7例中断治疗后疾病进展.死亡5例,其中3例为治疗有效后中断治疗者.患者最常见的不良反应为血小板减少,但可以自行恢复.其次为恶心、呕吐、乏力、周围神经毒性、带状疱疹等.结论 硼替佐米治疗难治性MM疗效确凿,患者耐受性好,但需要坚持足疗程治疗.
- [1]Richardson PG,Barlogie B,Berenson J,etc.A phase 2 study of bortezomib in relapsed, refractory myeloma.[J].2003,348(26).
- [2]Shigesaburo, Miyakoshi,Masahiro, Kami,Koichiro, Yuji,etc.Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.[J].2006,107(9).
- [3]Schenkein D,Dalton WS,Porter JB,etc.Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.[J].2005,352(24).
- [4]Orlowski RZ,Stinchcombe TE,Mitchell BS,etc.Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies.[J].2002,20(22).
- [5]Attaya, Suvannasankha,Gina G, Smith,Beth E, Juliar,etc.Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma.[J].2006,7(2).
- [6]Hulin C,Stoppa AM,Troncy J,etc.Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.[J].2006,91(11).
- [7]V J, Palombella,O J, Rando,A L, Goldberg,etc.The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B.[J].1994,78(5).